Arch Therapeutics, Inc. (ARTH)

1.1800 +0.0400 (+3.51%) As of 01:58PM EDT. Market open.

Arch Therapeutics, Inc.

235 Walnut Street
Suite 6
Framingham, MA 01702
United States
617 431 2313
https://www.archtherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 8

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Terrence W. Norchi M.D.	Co-Founder, Chairman, President & CEO	450.5k	N/A	1965
Mr. Michael S. Abrams	CFO & Treasurer	325k	N/A	1970
Dr. Rutledge Ellis-Behnke Ph.D.	Co-Founder & Scientific Advisor	N/A	N/A	N/A
Mr. Shawn Carlson	Vice President of Sales	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

Corporate Governance

Arch Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.